Draft US bill on foreign inspections circulated
This article was originally published in Clinica
A draft bill laying out requirements for country-of-origin labelling of medical devices and inspections of medical device plants is being circulated among Democratic members of the US House of Representatives.
You may also be interested in...
The app allegedly shared sensitive customer information with three China-based data analysis and collection firms.
Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.